# Section 4: Tzield Post-Market Adoption & Coverage Deep-Dive

*Tzield (teplizumab-mzwv) is the only agent in this landscape to reach the
market, so its commercial and access experience is the field's single empirical
data point on what happens **after** an antigen-specific / immune-tolerance
therapy is approved. Every lesson here is directly relevant to how an EoE pMHC
vaccine would be received by payers and patients.*

> **Note on mechanism:** teplizumab is an anti-CD3 monoclonal antibody — an
> antigen-*nonspecific* immunomodulator, not a peptide-MHC agent. It is the
> regulatory and commercial *precedent*, not a mechanistic twin.

---

## 4.1 Regulatory basis

- **FDA approval:** November 2022 — the **first disease-modifying therapy in
  T1D**, indicated to **delay onset of Stage 3 T1D** in adults and children ≥8
  years with **Stage 2 T1D** (≥2 islet autoantibodies + dysglycemia).
- **Pivotal basis:** TN-10 (NEJM 2019) delay-of-onset data; supported by the
  PROTECT Phase 3 (2023) C-peptide preservation in new-onset disease.
- **Designations:** Breakthrough Therapy (FDA), PRIME (EMA).
- **Global expansion:** China NMPA approval Sept 2025; UK MHRA Aug 2025;
  EU (branded *Teizeild*) approval Jan 2026. Approvals track years behind the US.
- **Developer/commercial chain:** MacroGenics → Provention Bio (2018 asset
  purchase) → acquired by **Sanofi for $2.9 billion (2023)**. Royalty interests
  further fragmented (DRI Healthcare, Ligand/Tolerance <1%). *Lesson: a
  first-in-class tolerance asset attracted a ~$3B acquisition on the strength of
  a single delay-of-onset indication.*

---

## 4.2 Price

- **List / WAC:** **$13,850 per vial**, ≈ **$193,900 for the 14-day course**.
- Priced **above** analyst expectations (SVB ~$115k; SMBC Nikko $70–80k),
  causing an immediate share reaction and explicit investor concern that
  pricing "could lead to insurance hurdles."
- Manufacturer justification: value of delaying a lifelong chronic disease.
- **UK NHS list price:** £10,939.12 per 2 mL vial.

---

## 4.3 Payer coverage & access architecture

- **Universal prior authorization.** Every payer policy reviewed requires PA,
  gated on strict documentation of **Stage 2 T1D**: ≥2 positive islet
  autoantibodies (GAD, IAA, IA-2A, ZnT8A, ICA) **plus** documented dysglycemia
  without overt hyperglycemia. This is a demanding, multi-test eligibility gate.
- **The screening bottleneck is the dominant access barrier.** Autoantibody
  screening is *not* part of routine care. Because ~90% of people who develop
  T1D have **no family history**, family-history-limited screening misses most
  eligible patients — general-population screening is needed but not
  reimbursed/standard. Canada's CDA-AMC review flagged that variable
  autoantibody-test access "may result in inequitable access."
- **Administration burden.** 14 consecutive daily **IV infusions**, BSA-dosed,
  with premedication and monitoring for **cytokine release syndrome** and
  **lymphopenia**, plus liver-enzyme monitoring — a substantial logistical and
  tolerability load for an asymptomatic patient.
- **Manufacturer mitigation:** COMPASS patient-support program; copay assistance;
  AAb-screening cost support (reportedly 8/10 commercially insured pay <$20 for
  screening).

---

## 4.4 Real-world uptake

- **Slow, gradual ramp.** Tzield accounted for just **1.2% of total T1D drug
  sales in 2023** (GlobalData) — "particularly low… due to substantial financial
  burden and limited long-term data."
- **Sanofi reported sales:** €54 million (FY2024); €18 million in Q3 2025 alone
  (+26.7% YoY, ~94% US), described as a "gradual uptrend… driven by continued
  growth in infusions supported by increased awareness and screening."
- **Long-run forecast:** GlobalData projects Tzield could become the
  **top-selling T1D drug at ~$4.8B across the 7 major markets by 2033**,
  contingent on broader screening and label/geographic expansion.
- **The uptake gate is screening, not demand.** Commentary consistently
  identifies **finding eligible presymptomatic patients** — not clinician
  willingness or efficacy doubt — as the rate-limiter. A SNOMED code for
  presymptomatic T1D exists (UK, since April 2024) but awareness is low.

---

## 4.5 The five transferable lessons for an EoE pMHC vaccine

1. **A disease-*delay* indication can win approval and a multi-billion-dollar
   acquisition** — you do not need to demonstrate cure. An EoE program can aim
   at preventing progression (e.g., to fibrostenosis) rather than symptom
   elimination.
2. **The companion-diagnostic / screening pathway can be a harder bottleneck
   than the drug itself.** Tzield's uptake is throttled by the absence of
   routine autoantibody screening. An EoE pMHC vaccine that requires HLA typing
   or allergen-sensitization testing must **co-develop and fund the screening
   pathway** from day one.
3. **Price high and payers respond with restrictive PA + demanding eligibility
   documentation.** Budget for a coverage-navigation program (a COMPASS
   analog) as a core commercial deliverable, not an afterthought.
4. **Administration burden matters disproportionately for
   asymptomatic/early-disease patients.** 14 daily infusions is a hard sell to
   someone who feels well. An EoE vaccine's **route and schedule** (few doses,
   subcutaneous/intradermal, outpatient) will materially shape adoption — a
   direct input to the patient-survey follow-on.
5. **First-in-class tolerance therapies ramp slowly.** Expect a multi-year
   adoption curve gated by awareness, screening infrastructure, and long-term
   data — plan runway and evidence-generation accordingly.